Increased plasma cholesterol, particularly that portion associated with LDL, is an established risk factor for coronary heart disease [1, 2] . As a consequence, it is widely recommended [3] that LDL-cholesterol be determined in individuals with increased total cholesterol. Because isolation of the LDL fraction requires ultracentrifugation, a technique not generally available in service laboratories, the concentration of LDL-cholesterol is usually calculated by the formula of Friedewald et al. [4] .
The Friedewald formula provides an adequate estimate of LDL-cholesterol for most fasting specimens but is known to be less reliable as triglyceride concentration increases [5] . Moreover, in patients with chronic renal failure, in whom an accumulation of remnant particles and increased concentrations of IDL-cholesterol have been found [6, 7] , the estimate is possibly further compromised [8] .
Here we report results on specimens obtained from patients on dialysis with chronic renal failure that show no greater disparity between measured and estimated LDL-cholesterol concentrations than those seen in other patient groups in which the Friedewald formula is frequently used. Additionally we have reexamined the effect of IDL and VLDL composition on the reliability of estimations made with the formula.
Two sets of blood specimens taken 6 months apart were obtained from 106 patients receiving hemodialysis or continual ambulatory peritoneal dialysis [9] . Within this 6-month period, some patients received an inhibitor of hydroxymethylglutaryl-CoA reductase, some an inhibitor of angiotensin-converting enzyme, some both treatments, and some placebo only. Blood collected after an overnight fast and separated within 4 h provided serum specimens for analysis.
Total cholesterol and triglyceride were assayed enzymically with reagents from Boehringer Mannheim. HDLcholesterol was assayed after precipitation of the apo B-containing lipoproteins with phosphotungstate and magnesium ions [10] . The performance of these assays was regularly certified by reference to samples provided by the Centers for Disease Control and Prevention, Atlanta, GA. Ultracentrifugation was carried out as described by others [11] for 15 h at 120 000g with a TFT 80.4 fixed-angle rotor in a Centrikon T-2070 centrifuge (Kontron Instruments). Cholesterol and triglyceride contents of supernatant fractions obtained after the tubes were sliced [11] were measured; the fraction floating at a relative density (d) of 1.006 was taken to represent VLDL and that floating at d 1.019 obtained by adjustment of 20 volumes of serum with 1 volume of NaBr solution (d ϭ 1.27, ϳ3.9 mol/L) was taken to represent VLDL plus IDL. The contents of IDL alone were calculated by subtraction. When in other experiments this technique was extended to permit sequential isolation of LDL and of HDL [11] , the mean recovery of total cholesterol was 90% (range 86 -95%) and of triglyceride was 92% (range 88 -95%).
LDL-cholesterol was calculated as total cholesterol Ϫ HDL-cholesterol Ϫ VLDL-cholesterol; VLDL-cholesterol was either measured directly (after ultracentrifugation) or calculated as 0.456 ϫ total triglyceride concentration expressed in mmol/L (Friedewald) .
Analysis of 204 specimens with complete data from the 106 patients showed concentrations (mmol/L) of total cholesterol of 3.16 -9.25 (median 6.00), triglyceride of 0.48 -7.74 (median 2.01), VLDL-cholesterol of 0.09 -3.78 (median 0.92), IDL-cholesterol of 0.15-1.58 (median 0.45), and HDL-cholesterol of 0.36 -2.28 (median 0.93). LDLcholesterol derived from ultracentrifugation data ranged from 1.13 to 7.27 (median 3.92) mmol/L.
Thirty-six specimens (18%) had a LDL-cholesterol calculated from the Friedewald formula that differed from the ultracentrifugation value by Ͼ10%. This proportion of specimens with significant error is similar to those proportions (15-19%) found in much larger series of patients of more diverse clinical conditions [12, 13] . The proportion is substantially less than the 42% of 45 individuals with chronic renal failure reported by others [8] , despite the lower lipid values in their series.
Recognition that the Friedewald formula is unreliable in the presence of chylomicronemia and hypertriglyceridemia has led to the use of various indices for the exclusion of such specimens. Total triglyceride concentration commonly is used [5] , although a low total cholesterol:triglyceride ratio has been proposed as a more relevant criterion for rejection [14] . Additionally, others have identified increased cholesterol:triglyceride ratios in VLDL and IDL and increased IDL-cholesterol alone as being associated with increased error in the formula [8] .
We plotted the number of errors detected against each index arranged in centiles (Fig. 1) . The median (range) for each index was: total triglyceride concentration, 2.01 (0.48 -7.74) mmol/L; total cholesterol:triglyceride ratio, 2.92 (0.86 -7.86); cholesterol:triglyceride ratio in VLDL, 0.75 (0.31-1.28); IDL-cholesterol 0.45 (0.15-1.58) mmol/L; cholesterol:triglyceride ratio in IDL, 2.69 (1.11-6.80). With total triglyceride concentration and total cholesterol:triglyceride ratio (by inverse ranking so that increased incidence of error was positively associated with the index), error detection was similar with the number of errors initially small but rising steeply from the 60th centile. By contrast, with the ratio of cholesterol:triglyceride in VLDL and in IDL and with IDL-cholesterol concentration, the errors were more evenly distributed among the centiles. Quantitatively, 18 errors (50%) were included when triglyceride concentration was 3.51 mmol/L (86th centile), total cholesterol:triglyceride ratio was 1.91 (81st centile), cholesterol:triglyceride ratio in VLDL was 0.82 (70th centile), IDL-cholesterol was 0.53 mmol/L (65th
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The ranking by total triglyceride concentration and total cholesterol:triglyceride ratio demonstrates that these values are far better suited as criteria for deciding whether it is valid to calculate LDL-cholesterol. Moreover, the results confirm that total triglyceride concentration alone seems to be the most simple and appropriate criterion to use, with total cholesterol:triglyceride ratio offering no improvement in discrimination.
In our study, 24 of 41 specimens (59%) with triglyceride concentration Ͼ3.2 mmol/L had an unreliable estimate of LDL-cholesterol from the Friedewald formula, with all but two being an overestimate. While such overestimation is typical of abnormal VLDL composition as seen in Type III hyperlipoproteinemia [5] , there appeared to be no clear association between cholesterol:triglyceride ratio in VLDL and the incidence of error (Fig. 1) . It seems improbable that the disparity between our results and those of others [8] could be explained by effects of drug treatment. Indeed, the conclusion was unchanged when the 50 specimens from patients on an hydroxymethylglutarylCoA reductase inhibitor were removed from analysis.
In summary, use of the Friedewald formula in a group of patients expected to give aberrant results provided reliable data in the majority of cases. Moreover, triglyceride concentration was a suitable index of reliability. However, restricting use of the formula to those specimens having a triglyceride concentration of Ͻ4.5 mmol (4 g)/L [13] included a group above the 80th centile in which the error rate exceeded 50%. Limiting use of the formula to those below the 80th centile and having a triglyceride concentration of Ͻ3.2 mmol (2.8 g)/L excluded the majority of errors and left 151 of 163 (93%) with a valid estimate. By contrast with the results of others [8, 14] , we found little influence of VLDL or IDL on the reliability of the Friedewald formula and no advantage with total cholesterol:triglyceride ratio as a discriminant.
The study of the effects of simvastatin and enalapril on serum lipoprotein concentrations in patients on dialysis, from which this work derives, was supported by a grant from Merck, Sharp and Dohme. The 204 specimens were first ranked separately by (a) triglyceride concentration (TRIG), (b) total cholesterol:total triglyceride ratio (CHOL/TRIG), (c) cholesterol: triglyceride ratio in VLDL (VLDL ratio), (d) IDL-cholesterol concentration (IDL), and (e) cholesterol:triglyceride ratio in IDL (IDL ratio). The centile rank for the 36 LDL-cholesterol results in error (i.e., those for which the Friedewald formula gave a result that differed from that of ultracentrifugation by Ͼ10%) was then found as shown. To provide a consistent comparison, an inverse ranking for total cholesterol:total triglyceride ratio was used.
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Technical Briefs monly reported cause of dysfibrinogenemia and, like other dysfibrinogenemias, is readily detected because of the associated prolonged thrombin and reptilase times [1] [2] [3] . The mutation alters the thrombin cleavage site such that release of fibrinopeptide A is delayed. However, fibrinopeptide release assays are difficult and do not directly confirm the molecular basis of the impaired fibrinopeptide release. We have therefore designed a rapid and technically simple PCR-based method for detection of the A␣16Arg3 His mutation. This allows reliable identification of a common dysfibrinogenemia that, in its heterozygous form, is usually asymptomatic and does not pose any substantial threat to the health of the patient. Application of this method will allow clinical laboratories to determine the molecular defect in many of the cases that they detect during coagulation studies.
We examined nine families with the A␣16Arg3 His mutation. These had been referred for further investigation when routine coagulation studies were consistent with dysfibrinogenemia. All procedures were carried out in accordance with the guidelines of our local ethics committee. Blood samples were collected into Na ϩ citrate Vacutainer Tubes (Becton Dickinson), and coagulation studies were performed by routine clinical tests for thrombin and reptilase times. There was considerable variation both within and between families in thrombin times [range 36 -70 s (reference range 20 Ϯ 2)] and reptilase times [range 45-72 s (reference range 20 Ϯ 2)]. In each case fibrinopeptide release assays [4] demonstrated reduced fibrinopeptide A concentrations with an additional earlier eluting peak. Either amino acid analysis of the abnormal fibrinopeptide or DNA sequence analysis then confirmed the mutation.
Genomic DNA was isolated from whole blood [5] . The oligonucleotides Fn1111␣ (ATT GCT GTT GCT CTC TTT TG) and Fn1309␣ (AAT CTC CTG CTT CCC CCG CT) were used to amplify a 199-bp region spanning exon 2 of the A␣ gene by PCR [6] . Each 100-L amplification reaction contained 50 mmol/L KCl, 10 mmol/L Tris-HCl, pH 8.3, 1.5 mmol/L MgCl 2 , 200 mol/L of each dNTP, 1 mol/L of each primer, 1 g of DNA template, and 2 units of Taq DNA polymerase (Boehringer Mannheim). Amplification was for 30 cycles with denaturation for 30 s at 94°C, annealing for 30 s at 60°C, and extension for 1 min at 72°C with a final extension at 72°C for 7 min. The PCR products were digested for 4 h at 37°C with 5 units of NlaIII according to the manufacturer's instructions (New England Biolabs). Typically 7 L of PCR product was diluted to 10 L by the addition of 0.5 L of 10 units/L NlaIII, 1 L of NEBuffer 4 (New England Biolabs), 1 L of 1 mg/mL bovine serum albumin, and 0.5 L of sterile distilled water. Digestion was assayed by gel electrophoresis in 2% agarose, 50 mmol/L Tris base, 45 mmol/L boric acid, 0.5 mmol/L EDTA for 30 -40 min at 100 V. Products were visualized by staining in 20 g/mL ethidium bromide for 5 min followed by transillumination at 302 nm.
The A␣16Arg3 His mutation changes the sequence CGTG to CATG creating an NlaIII cleavage site near the middle of the PCR product (Fig. 1, lower panel) . Cleavage at this site generated 104-bp and 95-bp products that were not resolved on the agarose gel, but were clearly separated from the uncut product. DNA from apparently healthy individuals remained uncut. The upper panel of Fig. 1 shows the restriction pattern produced from apparently healthy individuals (lanes 2 and 5) and the pattern produced by individuals heterozygous for the A␣16Arg 3 His (CGT3 CAT) mutation (lanes 3, 4, and 6). Additionally, the assay should be able to detect homozygotes because no uncut product should remain; however, appropriate controls were not available.
The mutation A␣16Arg3 His affects the thrombin cleavage site at the N-terminal of the A␣ chain. Normal cleavage at this site exposes the Gly-Pro-Arg (A) site, which interacts with a preformed, complementary site located in the C-terminal of the ␥ chain, thereby initiating polymerization [7] . The net effect of replacing the arginine at position 16 of the A␣ chain is only to delay the thrombin-catalyzed exposure of the A polymerization site. Therefore, it is not surprising that this mutation is usually asymptomatic. Despite this, two reported cases have been associated with mild bleeding tendencies [8, 9] . In these cases, the bleeding tendency generally can be attributed to additional abnormalities in other coagulation proteins. In fibrinogen Milano VI, the patient showed Upper panel, restriction digest of amplified A␣ chain exon 2 from affected and unaffected family members run on a 2% agarose gel for 30 -40 min at 100 V. Lane 1, X174/HaeIII molecular mass marker; lanes 2 and 5, DNA from apparently healthy individuals; lanes 3, 4, and 6, DNA from heterozygous individuals. Lower panel, DNA sequence showing the normal and the mutated sequence of A␣ chain exon 2. The mutation produces an NlaIII recognition site (underlined), and the arrow denotes where the enzyme cleaves. Numbers designate the amino acid position within the A␣ chain.
Clinical Chemistry 43, No. 11, 1997 defective platelet aggregation [8] , whereas in fibrinogen Birmingham, abnormalities in von Willebrand factor were seen [9] . The only reported case of this mutation in its homozygous form, fibrinogen Giessen I, is associated with more severe symptoms and displays a severe bleeding tendency and miscarriage [10] .
Dysfibrinogenemias with the A␣16Arg 3 His mutation are usually detected by prolonged thrombin-clotting times. Once detected, the mutation can be characterized by reversed-phase monitoring of fibrinopeptide release [4] . In patients with the A␣16Arg3 His mutation, the A peptide peak is reduced by half, and there is an additional earlier-eluting peak that represents the histidine-containing A peptide. Subsequent protein sequencing of the abnormal peptide is required to confirm this mutation. Although the method does provide a definitive result, the apparatus and technical expertise required are well beyond the scope of most clinical laboratories. With the method described here, the detection of this mutation, which in our experience accounts for 50% of all cases of dysfibrinogenemia, is straightforward, requiring only a simple PCR and restriction digest. The absolute identification of this mutation will enable the clinician to reassure the patient that their dysfibrinogenemia is unlikely to cause any bleeding disorder. Increased understanding of bone turnover has led to the development of several biochemical tests of bone metabolism. Among the biochemical indexes of bone resorption is measurement of urinary excretion of pyridinoline (Pyr) and deoxypyridinoline (Dpyr), molecules that cross-link the collagen chains and are released into the systemic circulation after the breakdown of mature bone collagen [1] [2] [3] . Because they are not metabolized in vivo, they are excreted directly into urine in free (ϳ40%) and peptidebound forms (ϳ60%) [4] . Methods to measure cross-links in urine involve mainly two technical approaches: HPLC analysis, which, after hydrolytic and purification steps, allows the determination of the total forms of cross-links [5] [6] [7] , and monoclonal antibody immunoassay methods able to quantify the sum of free Pyr and Dpyr or only the free Dpyr form [8, 9] . The quantification of total or free cross-links forms provides, in any case, similar clinical information [9, 10] .
Here we report the evaluation of the Cross Links TM HPLC kit recently introduced by Beckman Labs. to quantify the total forms of Pyr and Dpyr. We compared the performance of this procedure with the ChromLinks TM HPLC method from Bio-Rad Labs. In addition we investigated the determination of free Dpyr by the Cross Links method by comparing it with the Pyrilinks TM -D immunoassay (Metra Biosystem) [11] . After the Beckman procedure 0.25 mL of urine was hydrolyzed with 0.25 mL of HCl (12 mol/L) (R1 reagent) at 115°C overnight. After the addition of 0.5 mL of the internal calibrator solution and 2 mL of 1-butanol (R2 reagent), samples were loaded onto solid-phase columns and washed with 9 mL of R3 reagent (a mixture of butanol:water:acetic acid). After the addition of 0.5 mL of an organic solvent reagent (R4) to clean up the columns from the previous R3 reagent, cross-links were eluted with 0.5 mL of the extraction reagent (R5) containing heptafluorobutyric acid in water, and 50 L was injected into the HPLC. Unlike the Bio-Rad assay, which employs gravimetric columns, purification of urine is carried out under vacuum by solid-phase extraction, with a notable time saving and minimal solvent exposure for the technical staff.
The HPLC equipment consisted of a Beckman System Gold Model 116 on line with an autosampler Model 507 and a Shimadzu Model RF 551 fluorometric detector with excitation at 295 nm and emission at 395 nm. The chromatographic separation lasted 10 min (Fig. 1) and was performed on a reversed-phase column (100 ϫ 4.6 mm) in isocratic mode, at a flow rate of 1.0 mL/min. The eluting 2186 Technical Briefs solution was prepared by mixing the stock buffer (heptafluorobutyric acid solution) purchased from Beckman with acetonitrile and water in the proportion 0.25:0.65:9.1 (by vol). The column was thermoregulated at 37°C.
The intraassay CVs (n ϭ 10) for a urine pool with Pyr ϭ 500 pmol/mL and Dpyr ϭ 89 pmol/mL were 3% and 4.9%, respectively, and for Pyr ϭ 950 pmol/mL, Dpyr ϭ 193 pmol/mL 3.4% and 2.8%, respectively. The interassay variation was calculated from the analysis of the same urine pools for 7 consecutive days. The CVs for Pyr and Dpyr were 5.5% and 8.7% for the lower concentrations and 4.0% and 5.2% for the higher concentrations. The mean recoveries were 95% Ϯ 4.6% for Pyr (n ϭ 3) and 99.2% Ϯ 2.0% for Dpyr (n ϭ 3). The assay was linear (r ϭ 0.999) in the tested ranges (0 -3000 pmol/mL and 0 -500 pmol/L for Pyr and Dpyr, respectively). A signal-to-noise ratio of 3 (detection limit) was achieved at 1 pmol injected.
Comparison of the Beckman HPLC kit vs Bio-Rad on 50 urine samples from postmenopausal women (57 Ϯ 5.7 years) who were referred to the Orthopaedic Division of our Institute yielded the following equations: Bio-Rad ϭ 0.970 (Ϯ 0.0175) ϫ Beckman ϩ 8.0 (Ϯ 14.59) (ϮSE), r ϭ 0.994, S x͉y ϭ 45.7 for Pyr, and Bio-Rad ϭ 0.870 (Ϯ 0.0274) ϫ Beckman ϩ 17.4 (Ϯ 5.56), r ϭ 0.983, S x͉y ϭ 17.5 for Dpyr. The slight underestimation of the Bio-Rad kit may be imputable to the lack of an internal calibrator to minimize handling errors.
Comparison of the concentrations of free forms of cross-links measured with the Cross Links with the mean of duplicate results of the Pyrilinks-D kit in 35 urine samples yielded: ELISA ϭ 0.865 (Ϯ 0.0519) ϫ Beckman ϩ 3.71 (4.489), S x͉y ϭ 10.3 (r ϭ 0.947). Free Dpyr concentrations found with both kits represented ϳ40% of the corresponding total form, in agreement with data reported in literature [11] .
We conclude that the Cross Links HPLC kit provides accurate results with a short and automated analysis (10 min) that can be performed overnight, thus reducing the technician time. We proved also that the detection limit of the Beckman kit allows the quantification of the free forms of cross-links (avoiding the time-consuming hydrolysis step) with a simple open monopump HPLC system. Despite the comparable costs (HPLC ϳ$29/sample vs the EIA ϳ$35/sample), the possibility of achieving in a single run the quantification of Pyr, Dpyr, and their ratio contributed to making this procedure an attractive alternative to the easily performed immunoassay. In recent years concern over the adverse effects of low concentrations of lead on children has increased. In 1991, the CDC reduced the acceptable blood lead concentration from 250 g/L to 100 g/L and recommended screening of all American children Ͻ6 years old for lead poisoning [1] . Graphite furnace atomic absorption spectroscopy is Fig. 1 . Chromatographic separations of calibrator mixture containing Pyr (514 pmol/mL), Dpyr (56 pmol/mL), and internal standard (IS) (A), hydrolyzed urine sample (Pyr ϭ 820 pmol/mL, Dpyr ϭ 185 pmol/mL) (B), and nonhydrolyzed urine sample (Pyr ϭ 260 pmol/mL, Dpyr ϭ 53.2 pmol/mL) (C).
Convenient
HPLC analysis was performed on a reversed-phase column at 37°C, with a flow rate of 1 mL/min and injection volume of 50 L. Fluorescence detection: ex ϭ 295 nm, em ϭ 395 nm.
Clinical Chemistry 43, No. 11, 1997 the most common method of measuring lead in blood, but the CDC has encouraged the development of other methods that could be used for mass population screening or near-patient testing. Such methods should be portable, cheap, and easier to use than graphite furnace atomic absorption spectroscopy as recommended by CDC Program Announcement 269, 1992.
The electrochemical technique of stripping voltametry at a mercury electrode has also been used for blood lead analysis. Commercially available instruments based on this method have been used widely but have insufficient accuracy and precision for measuring lead at low concentrations [2] . Recently, improvements have been made in the electrochemical measurement of blood lead. Ostapczuk [3] and Jagner et al. [4] obtained good accuracy and precision at low concentrations by potentiometric stripping analysis. They used a mercury-coated graphite electrode that must be cleaned between each analysis, and their testing procedure required stirring of the acidified blood solution.
An approach to stripping analysis that simplifies the testing is the use of disposable electrodes, which can be used once and then thrown away. Microarray electrodes have properties that make them especially suitable for this application. They have high current densities in unstirred solution, have a high signal-to-background ratio, and are not affected by dissolved oxygen. Furthermore, they can be made cheaply by a combination of screen printing and laser photoablation (international patent WO 91/08474) [5] . In sufficiently large numbers, e.g., 10 6 electrodes per year, they could be manufactured for ϳ$1 each. Recently Feldman et al. [6] described the use of disposable microelectrode arrays for measuring lead in blood. Their testing protocol required that the electrodes be preplated with mercury. They also found that the electrodes responded differently to different blood types, and they had to use standard additions to determine the lead concentration.
Here we report a simplified procedure for the use of disposable microelectrodes to measure lead in blood. Mercury is not preplated or added to the test solution but is contained in a precoated layer on the electrode and coplates with the lead. These devices can be precalibrated, removing the need to perform standard additions.
The disposable electrodes were similar to those described by Feldman et al. The procedure for performing a blood lead test involved two steps, acidification and electrochemical measurement. The initial acidification step involved the addition of 200 L of blood to 2.0 mL of 0.9 mol/L HCl in a 20-mL polystyrene vial. The vial was then mixed briefly by hand and put on a bottle roller for ϳ5 min to ensure complete release of the bound lead before the blood was tested. Earlier experiments showed that 1 min was sufficient for complete release, but results were unchanged for up to 45 min.
The electrochemical testing was carried out with an Autolab (EcoChemie) in the differential pulse mode. Acidified blood (75 L) was pipetted to a disposable electrode, and deposition was effected by polarizing the electrode at Ϫ800 mV for 165 s. The stripping sequence used a pulse amplitude of 50 mV, step 5 mV, pulse width 3 ms, and trough width 120 ms. Lead-stripping peak heights were measured with use of the Autolab software.
The linear response of the electrodes was tested by the addition of various amounts of Pb(NO 3 ) 2 (Aldrich AA standard) to portions of a blood sample to give a range of lead concentrations up to 1000 g/L. The exact lead concentration of each supplemented blood sample was measured by atomic absorption. Each blood was tested with 5 disposable electrodes. A graph of peak current against lead concentration was linear up to ϳ600 g/L with a slope of 0.0070 A per g/L and an intercept of 0.212 A. The intercept may result from the presence of lead in the mercury layer on the electrodes. This graph was used as a calibration curve for subsequent electrodes.
Blood samples were selected from those sent to the Regional Toxicology Laboratory for clinical investigation or occupational monitoring of lead exposure [7] . In the majority of cases the specimens had been anticoagulated with potassium EDTA, although some pediatric samples had been collected into Li heparin. All the specimen collection tubes used were known to be free of lead contamination.
Blood lead was measured by electrothermal atomic absorption spectroscopy with the use of a Varian Spectra AA 44 spectrophotometer equipped with deuterium background correction and a GTA-96 graphite furnace (Varian UK). Blood was assayed directly after suitable dilution with an ammonium nitrate/ammonium phosphate modifier solution, with calibration against matrix-matched calibrators. Batch accuracy was monitored by the use of blood reference materials with accurately assigned values [7] (UK Supra Regional Assay Service Trace Elements Laboratories). Laboratory performance was assessed by participation in two national external quality-assessment schemes: NEQUAS lead and cadmium in blood (Wolfson EQA Laboratories) and TEQAS Trace Elements (Robens Institute, University of Surrey, Guildford).
The accuracy of the electrodes was determined by doing a correlation study with 20 venous blood samples, the lead concentrations of which had been determined as described above. Each blood was tested with 2 electrodes.
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The lead concentrations were calculated from the leadstripping peaks with the use of supplemented blood calibration. The results of the correlation study (Fig. 1) show an excellent agreement between the disposable electrodes and the comparison method. All 40 measurements were within 20 g/L of the comparison method results. Of the 22 measurements on blood samples with lead concentrations Ͻ200 g/L, 21 of them were within 10 g/L of the comparison method result. The low intercept and slope close to 1 demonstrate that the supplemented blood calibration works well.
The precision of the electrodes was tested with 3 venous blood samples with lead concentrations of 50, 110, and 250 g/L. Each blood sample was acidified once, and the solution was tested with 10 electrodes. The observed CV was 11.9%, 7.2%, and 2.7%, respectively.
In The immunosuppressant drug tacrolimus (FK506), which exhibits 50 -100 times the potency of cyclosporin A, is proving to be highly effective in preventing rejection in solid-organ transplantation [1] . However, because of a narrow therapeutic range, variable pharmacokinetics, and potential drug interactions, continual therapeutic drug monitoring (TDM) of tacrolimus is essential [2] . Recently, we published a report that detailed the development of a specific, sensitive method for quantification of tacrolimus concentrations in blood [3] . This methodology, which utilizes HPLC in combination with tandem mass spectrometry (LC-MS 2 ), was found to have greater specificity, lower detection limits, and a more rapid turnaround time than existing immunoassays. These attributes make this methodology ideal for TDM of tacrolimus.
Since our initial report, several modifications that have further improved the assay for TDM have been implemented. The use of a 100 ϫ 2 mm C 8 column (rather than a 30 ϫ 2 mm C 4 column), combined with a higher flow rate (400 L/min, compared with 100 L/min) and postcolumn splitting, has reduced the chromatographic assay time from 4 to 2 min. Although the retention times of the analytes are similar with both methods, intermittent late-eluting peaks observed previously are no longer present, allowing shorter analysis time. In addition, the use of a single point calibrator (i.e., linear through zero) at 10.0 g/L and two internal quality controls (5.0 and 20.0 g/L), compared with a seven-point calibration curve and three internal quality controls, has reduced the analysis time further. Previously, we reported an overall turnaround time of 2.5 h for a batch of 20 samples (10 patient samples). The modified method allows an analysis Because of the sensitivity (low detection limit) of the method, we have been able to halve the sample volume of blood required to perform the assay (i.e., from 1000 to 500 L). The postcolumn split of solvent flow into the mass spectrometer (1:12) provides enhanced stability of the mass spectrometer response for long periods of time (Ͼ12 h), without compromising assay sensitivity. For this reason a postcolumn split of solvent flow is now routine for all analytical assays conducted in this laboratory.
The imprecision and accuracy of the modified method were assessed with internal QCs at three concentrations (0.25, 5.0, and 20.0 g/L). Over the concentration range studied, within-day and between-day imprecision were Ͻ11%, and analytical recovery was between 98% and 105%. A comparison of these values with those reported in our original paper, with different concentrations (0.3, 8.0, and 80.0 g/L), revealed similar results (Table 1 ). In addition to internal quality controls, the modified method was evaluated against the European Quality Assessment Scheme for tacrolimus. This evaluation involved the comparison of unknown weighed-in concentrations (n ϭ 12) with the results determined by our method. The evaluation showed good correlation (y ϭ 0.994x ϩ 0.398, r ϭ 0.996, mean bias ϭ 0.258 g/L) and no significant difference (P ϭ 0.97) between our results and weighed-in concentrations.
As a cost benefit, the viability of repeated use of the C 18 solid-phase extraction cartridges was investigated by reanalyzing randomized patient samples on used cartridges. A comparison of first use and second use of the cartridges revealed that no significant differences existed between the concentrations measured by the LC-MS 2 (y ϭ 1.03x ϩ Ϫ0.127, r ϭ 0.993, mean bias ϭ Ϫ0.167 g/L, n ϭ 95). As a result of the large number of patient samples being analyzed annually within the laboratory (i.e., Ͼ2000), the 20% reduction in consumable expenditure achieved through a single reuse of the solid-phase extraction cartridges represents substantial cost savings.
These modifications have led to a more time-and cost-efficient TDM service for tacrolimus, without a compromise in assay results. The specifications of our method (i.e., specificity, accuracy, and precision) meet the analytical requirements described by Shaw et al. [4] for the measurement of immunosuppressant drugs. Further, the method's specificity for the parent drug lends itself to detailed pharmacokinetic studies and studies of potential drug interactions involving tacrolimus. With the increased knowledge of tacrolimus treatment in organ transplantation, the proposed therapeutic range for the drug has been reduced. Our improved method, which provides accuracy and precision at these lower concentrations, is therefore timely, as an important means of supporting the clinical management of patients undergoing organ transplantation.
This project was supported in part by the Princess Alexandra Hospital Research and Development Foundation. PCR-single-strand conformation polymorphism (SSCP) analysis is an attractive technique used to screen for unknown mutations because of its simplicity and widespread applicability [1] . The technique relies on singlenucleotide variations modifying the conformation of single-stranded DNA and therefore its mobility in polyacrylamide gels. The detection of these conformers is performed either by autoradiography or by nonisotopic methods such as silver-staining [2] , ethidium bromidestaining [3] , chemiluminescence [4] , or fluorescence [5] .
Optimization of Nonisotopic PCR-
In this paper, we report a nonisotopic PCR-SSCP method with the use of the Pharmacia MultiPhor TM (Pharmacia Biotech) electrophoresis unit for sensitive, reproducible, and cost-effective experiments that can be performed at high throughput. This method was established to analyze the 12 exons of the glucokinase (GCK) gene to identify mutations involved in maturity-onset Table 1 . Imprecision and analytical recovery of the original and modified LC-MS 2 whole-blood assays. The 12 GCK exons [6] were amplified by PCR (fragments ranging from 145 to 367 bp), as reported previously [2] , either on Geneamp TM 9600 (Perkin-Elmer) or PTC100 TM (MJ Research) DNA thermal cyclers. Forty-six known mutations [6 -8] were used to establish the optimal electrophoretic conditions for the 12 PCR fragments. Two types of precast polyacrylamide gels, allowing the analysis of 34 and 23 DNA samples, respectively, were used: nondenaturing gels [Cleangel-HP ® , 10% total acrylamide (T) concentration, 2% total extent of cross-linking (C); ETC Elektrophorese-Technik] and partially denaturing gels (Excelgel ® , 7.5% T, 3% C, Pharmacia Biotech). Electrophoresis was performed at temperatures of 6 -20°C, the length of assays depending on size and GC content of the PCR fragments. For all exons except exon 9, samples were run on Cleangel-HP, rehydrated in Delect (Table 1) . Gels were stained with a silver-staining kit (Silver Staining Kit Plus One ® ; Pharmacia Biotech) and then wrapped in cellophane (soaked in a solution of 100 mL/L glycerin and 100 mL/L acetic acid) for preservation.
All nucleotide changes previously identified [8] were detected. Fig. 1 shows the electrophoretic profile of exon 10. The effect of different electrophoretic conditions was evaluated from the number of bands characteristic of a given PCR product, their sharpness, and resolution. The purification of our PCR products tested on exons 6, 9, and 10 (data not shown) did not provide an increase in sensitivity, contrary to other published results [9] . Indeed with specific PCR products, in addition to two conformers, bands resulting from the interactions between PCR primers and the single-stranded DNA were visualized and provided an easier analysis of the electrophoretic profile.
The protocol used for the GCK gene allowed us to establish a successful strategy for the development of PCR-SSCP on other genes such as BRCA1 (breast cancer 1, data not shown) on the basis of GC content and the length of PCR products. We found high sensitivity, especially in fragments generally difficult to test with the use of the PCR-SSCP technique, i.e., larger than 250 bp and presenting a high GC content (Ն60%). Lower detection limits and reliability of the detection of mutations by this PCR-SSCP analysis may be explained by multiple factors: (a) the use of precast gels; (b) the efficient temperature regulation with an independent thermostatic circulator that provides a wide range of precise running temperatures from 6 to 20°C and avoids the addition of glycerol to the gels often reported as decreasing the effects of temperature variability [10] ; and (c) the use of partially denaturing conditions with a temperature varying from 6 to 12°C, which increases the sensitivity of PCR-SSCP analysis, particularly for large or GC-rich fragments (exon 9). We hypothesize that mild denaturing conditions extend the exposed surface area of single-stranded DNA, which tends to assume a folded configuration in the complete absence of denaturing agents. Therefore, detection of locally confined structural differences in PCR fragments is improved.
Thus, the lack of detection often encountered with the PCR-SSCP analysis, as compared with other current technologies for the study of large fragments, is overcome in these conditions. Moreover, screening for mutations on the MultiPhor system is not expensive considering the gel-loading capacity, apparatus, and reagent prices as Step 1 15 min
Step 2 1 h 10 min
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Step 3 compared with fluorescent methods that require an automatic sequencer. Contrary to isotopic PCR-SSCP analysis, which is less reproducible, only a single run is routinely required to screen each exon.
In conclusion, PCR-SSCP analysis on the MultiPhor appears to be a useful and reliable tool in screening for unknown sequence variations at a high throughput and is especially adapted for laboratories that cannot perform fluorescent PCR-SSCP analysis on an automatic sequencer. An easy, nonradioactive detection method is required more than ever because of genetic diagnosis programs, in which routine screening for mutations will become more important for healthcare purposes. single-strand conformation polymorphism protocol using a direct blotting electrophoresis, a chemiluminescent detection system, and a multiplex approach. PCR Methods Appl 1994;4:52-5.
Multiple fluorescence-based PCR-SSCP analysis using internal fluorescent labeling of PCR products. BioTechniques 1996;21:510 -9. 6. Stoffel M, Froguel P, Takeda J, Zouali H, Vionnet N, Nishi S, et al. Recent data suggest that hyperhomocysteinemia is associated with an increased risk for premature vascular disease. Total plasma homocysteine (tHcy) may be increased by impaired activity of enzymes or suboptimal availability of B vitamins [1] .
Homocysteine transsulfuration reactions are catalyzed by the enzymes cystathionine ␤-synthase and cystathionine lyase in the presence of coenzyme vitamin B 6 , and remethylation of homocysteine is performed by the enzymes methionine synthase and betaine-homocysteine methyltransferase with vitamin B 12 as a coenzyme for the former enzyme. 5-Methyltetrahydrofolate (5-methyl-THF) or betaine are methyl donors during remethylation. The enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR) with coenzyme FADH 2 synthesizes 5-methyl-THF from 5,10-methylenetetrahydrofolate (5,10-MTHF) [2] . The postmethionine load (PML) abnormal tHcy increments may reflect suboptimal plasma vitamin B 6 or deficiency of cystathionine ␤-synthase [3] . The present report describes the effects of methionine loading on serum and erythrocyte folate, tHcy, and related thiols in smokers and nonsmokers.
We recruited 63 apparently healthy smokers [ages 37.8 Ϯ 0.8 years; body mass index (BMI), 25.4 Ϯ 0.5; male/female, 39/24; cigarettes/day, 16.2 Ϯ 0.8; smoking period (years), 19.7 Ϯ 0.7], 44 nonsmokers (ages 37.8 Ϯ 1.0 years; BMI, 24.5 Ϯ 0.5; male/female, 26/18), and 23 former smokers who refrained from smoking for Ն3 months (ages 39.5 Ϯ 1.0 years; BMI, 27.7 Ϯ 0.5; male/ female, 18/5) in the study. BMI and age of the participants were not statistically different. Informed consent was obtained from the participants, and the study was approved by the regional ethics committee.
Blood sampling and the methionine loading test were performed as described previously [4] . Participants were asked to eat a light breakfast or lunch with low contents of fats and proteins. Serum and erythrocyte folate and vitamin B 12 were measured by a Dualcount, solid-phase, no-boil RIA developed by Diagnostic Products. tHcy, cysteine, and cysteinylglycine were measured according to the method described previously [5] .
The Mann-Whitney U-test was applied to investigate the differences between the groups, and the Wilcoxon Fig. 1 . PCR-SSCP analysis of a GC-rich DNA fragment of the GCK gene.
SSCP profiles on exon 10: Lane 1 corresponds to a negative control, lanes 2-4 show samples carrying, respectively, mutations Stop466Leu, Ala450Thr, and Ser498 -1G3 C. *, additional conformers present on samples carrying a mutation.
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Technical Briefs signed rank test was used to explore changes within the groups during methionine loading. Significance of difference between more than two groups was estimated by analysis of variance with the use of the Bonferroni/Dunn procedure. StatView for the Macintosh developed by Abacus Concepts was used for statistical calculations.
The concentrations of serum and erythrocyte folate of smokers were significantly lower than those of nonsmokers (P Ͻ0.05) ( Table 1) . Lower intake of fruits and vegetables, free radicals in cigarette smoke, and increased excretion of folates may have contributed to a gradual decline in the concentration of serum and erythrocyte folate [6 -9] . An 11-16% reduction in the concentrations of serum folate was detected during methionine loading in smokers as well as in nonsmokers 2 h (P Ͻ0.01 and Ͻ0.001, respectively) and 6 h afterwards (P Ͻ0.01 and Ͻ0.001, respectively) ( Fig. 1, A) . A significant decrease in serum folate of former smokers was observed after 6 h (P Ͻ0.01) (not shown in the figure). A drop in the concentration of serum folate may have occurred because of the reduced activity of enzyme MTHFR. Methionine loading increases the concentration of S-adenosylmethionine, and increased concentrations of S-adenosylmethionine inhibit the reductase activity of MTHFR [10] .
Women had higher concentrations of serum folate than men (P Ͻ0.05) (data not shown). Nonsmokers had higher concentrations of serum folate than former smokers (P Ͻ0.01), but the difference in erythrocyte folate was not statistically different. Former smokers may not exhibit a significant change in serum folate until erythrocytes gradually accumulate folate to an optimal amount during the period of smoking cessation.
The concentrations of erythrocyte folate in smokers and nonsmokers remained unaffected during methionine loading (Fig. 1, B) , but a significant reduction in erythrocyte folate was detected in former smokers after 2 h (P Ͻ0.05) (not shown in the figure). Because 5-methyl-THF makes up ϳ40 -50% of total folate polyglutamates in erythrocytes, minor changes in the concentration of 5-methyl-THF may not influence substantially total erythrocyte folate.
Mean tHcy concentrations were significantly lower in women than in men (P Ͻ0.01); the significance disappeared when data were analyzed for male smokers vs female smokers (P ϭ 0.07) and male nonsmokers vs female nonsmokers (P ϭ 0.09). Smokers had slightly higher concentrations of tHcy than nonsmokers, but the difference was not significant even if data were analyzed separately for gender (data not shown). Previously, it has been reported that heavy smokers have significantly higher concentrations of tHcy than nonsmokers [11] .
The mean concentration of tHcy increased, and plasma concentrations of cysteine and cysteinylglycine decreased during methionine loading, as shown previously (Fig. 1 , C, D, and E) [5] . Large doses of methionine given to mice and rats seem to perturb activity of enzymes and concen- 1997 trations of amino acids involved in methionine metabolism [12, 13] .
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The 2-h PML response was abnormal (⌬tHcy concentration Ͼ90th percentile) in 10% of smokers, 9% of former smokers, and 7% of nonsmokers. The 6-h PML response was abnormal in 10% of smokers, 9% of former smokers, and 9% of nonsmokers. The concentrations of serum vitamin B 12 in smokers, nonsmokers, and former smokers (338, 353, and 356 pmol/L, respectively) were not significantly different, and the PML concentrations did not change significantly in the groups (data not shown).
We conclude that smokers have lower concentrations of serum and erythrocyte folate than nonsmokers and that methionine loading decreases serum folate in all groups. The traditional method for DNA separation is slab gel electrophoresis. Because slab gel electrophoresis, which involves the casting, loading, running, and staining of the gel is labor-intensive and time-consuming, high-resolution capillary electrophoresis (CE) has become an attractive alternative. CE, by contrast to conventional electrophoretic techniques, is capable of rapid, automated, reproducible, and high-resolution separation of minute amounts of DNA samples. To separate DNA fragments by CE, polyacrylamide gels or liquid buffers containing soluble polymers are used. Soluble polymers, such as hydroxyethyl cellulose, hydroxypropylmethyl cellulose, and methyl cellulose act as effective molecular sieves and allow for separation of DNA according to size [1] . CE has recently shown promising results for the analysis of double-stranded DNA such as restriction fragment length polymorphisms and polymerase chain reaction (PCR) products [2, 3] .
The insertion (I)/deletion (D) of a 287-bp sequence polymorphism within intron 16 of the gene for angiotensin-converting enzyme (ACE) is strongly associated with serum ACE concentrations [4] . The D allele has been identified as a risk factor for the development of coronary heart disease and myocardial infarction [5] . In addition, the deletion polymorphism has been associated with either microalbuminuria or overt nephropathy in diabetic patients [6, 7] . Here we report a sensitive, simple, rapid, and nonisotopic procedure for identification of ACE I/D polymorphism by CE.
Amplification of genomic DNA ACE I/D polymorphism PCR products of a 190-bp fragment in the absence of the insertion and a 490-bp fragment in the presence of the insertion were generated. The sense oligonucleotide primer was 5Ј-CTG GAG ACC ACT CCC ATC CTT TCT-3Ј, and the antisense primer was 5Ј-GAT GTG GCC ATC ACA TTC GTC AGA T-3Ј [8] . The PCR mixture contained 10 mmol/L Tris-HCl (pH 8.8), 50 mmol/L KCl, 1.5 mmol/L MgCl 2 , 1 mL/L Triton X-100, 200 mol/L each of the four deoxynucleotides, 1 mol/L each of the primers, and 3 U of Dynazyme (Finnzymes) in a final volume of 50 L. To enhance genotyping and to prevent misclassification of heterozygous individuals, we added 50 mL/L dimethyl sulfoxide to the reaction mixture [9] . Blank controls, containing no genomic DNA, and positive controls (ID) were also run with each set of amplification. The amplification cycle was performed on a PTC-100 thermal cycler (MJ Research). After an initial denaturation at 96°C for 3 min, the DNA was amplified by 30 PCR cycles-each consisting of denaturation at 94°C for 1 min, annealing at 65°C for 1 min, and extension at 72°C for 2 min-followed by a final extension at 72°C for 5 min. PCR products were directly analyzed by CE without being desalted or cleaned up.
CE separations were carried out with the use of the HP 3D Capillary Electrophoresis System (Hewlett-Packard). CEP-coated fused-silica capillaries provided with the pGEM Double Stranded DNA Analysis Kit (HewlettPackard) of 56 cm effective length and 64.5 cm total length were used. The separation/flush buffer consisted of 89 mmol/L Tris, 332 mmol/L boric acid, and 2 mmol/L EDTA at pH 7.4 with additives of 15 g/L hydroxyethyl cellulose (Hewlett-Packard). The buffer was prepared according to the manufacturer's recommendation, filtered, and degassed by sonication. The cathode was set on the injection side, the anode on the detection side. Samples were introduced into the capillary by electrokinetic (Ϫ10 kV for 30 s) injection, and the separation was conducted at constant voltage of Ϫ22 kV (340 V/cm). The capillary was held at 20°C throughout the experiment, and ultraviolet absorbance was monitored at 258 nm. Before each injection, a 10-min buffer wash was performed to ensure column cleanliness and reproducibility. A typical assay of samples lasted for 30 min. The identification of the various DNA fragments by size was obtained by plotting log bp vs 1/migration time. Fig. 1A shows an electropherogram of the separation of pGEM DNA calibrator with the use of a 15 g/L hydroxyethyl cellulose-filled capillary at Ϫ22 kV. The separation conditions were optimized in several preliminary experiments with electrokinetic and pressure injection; electrokinetic injection gives higher resolution. The separation conditions in Fig. 1A were sufficient for the rapid and complete separation of the pGEM sample, which contained 15 fragments ranging from 36 to 2645 bp. The DNA calibrator was run before the samples to ensure proper calibration of the analysis. Fig. 1B shows an example of a sample from a heterozygous individual, who expresses both 490-and 190-bp fragments. To confirm the accurate identification of the ACE gene polymorphism, we ran 10 samples, and all genotypes determined by CE were consistent with the results obtained by agarose gel electrophoresis.
We have demonstrated excellent separation efficiency for PCR products of the ACE gene by CE, in substantially shorter analysis time than by slab gel electrophoresis. Several investigators have recently reported that PCR analysis by CE may be hindered by salt in the reaction mixture, so salt must be removed before the CE analysis [10] . However, in the present study the ACE gene PCR products were analyzed directly by CE without further sample treatment, which saves time and resources. In addition, samples can be loaded onto an autosampler and run overnight, unattended, and analyzed data are directly entered into computer. In our studies, one coated capillary column lasted for Ͼ1 month and was used for Adrenoleukodystrophy (ALD) is an X-linked recessive disorder characterized by progressive demyelination of cerebral white matter and adrenal insufficiency. ALD is the most common peroxisomal disease, afflicting 1 in 20 000 male newborns. Patients with childhood ALD manifest changes of character or behavior and a decline of intelligence and visual or motor dysfunction as the first symptoms during school age. Most of them lapse into a vegetative state and die within several years of onset [1] .
Patients with all clinical subtypes, including childhood ALD, adolescent ALD, adult ALD (cerebral type), adrenomyeloneuropathy, and Addison disease without neurological symptoms, have defects in the ALD gene [2] . Defective activity of peroxisomal lignoceroyl-CoA ligase is considered to lead to the accumulation of very long chain fatty acid (VLCFA) in various tissues and fluids as a secondary phenomenon [3, 4] .
Dietary erucic acid (C 22:1 ) therapy may help prevent neurological deterioration in presymptomatic boys [5, 6] . Patients in the early or presymptomatic stages may be candidates for bone marrow transplantation [5, 7] . Gene therapy may also become possible. Screening for ALD, especially in the presymptomatic stage, will be important when these therapeutic methods are established, as in the cases of phenylketonuria or maple syrup urine disease.
ALD is usually diagnosed by plasma VLCFA analysis [1, 8] , sometimes followed by measurement of ␤-oxidation activity in cultured skin fibroblasts [9] and mutation analysis of the ALD gene [2, 10 -16] . However, screening requires a simpler and more economical method to deal with a large number of subjects. Utilization of a dried blood spot on filter paper for VLCFA analysis was reported previously [17] . Here, we describe an easy method of VLCFA analysis of dried blood spots on filter paper and discuss the possibility of screening for ALD.
Sep-Pak ® silica cartridges for solid-phase extraction (VAC/1cc, part no. 23595) were purchased from Waters. n-Hexane and methyl-tert-butyl ether (MTBE) were prepared to make solution A (n-hexane/MTBE, 96:4, by vol) and solution B (n-hexane/MTBE, 200:3, by vol). Sep-Pak cartridges were preactivated by 1 mL of solution A followed by 3 mL of n-hexane.
A dried blood spot on Guthrie filter paper, equivalent to 100 L of blood, was added to a tube containing 0.25 mL of distilled water and 2.5 mL of chloroform/methanol (1:1, by vol) and soaked. The sample was then left for 1 h at room temperature after being shaken for a few minutes. After centrifugation, the eluent containing lipids was placed in a fresh tube and 1.25 mL of chloroform and 0.75 mL of distilled water were added. These contents were shaken for 3 min at room temperature and centrifuged for 3 min. The lowest fraction, containing total lipids, was aspirated and concentrated by evaporation. The residue was heated with 1 mL of 50 mL/L concentrated HCl in methanol at 100°C for 1 h [17] . There was no significant difference in the efficiency of methanolysis for 1 h or 2 h at 100°C. Fatty acid methyl ester was extracted with 2 mL of n-hexane and concentrated by evaporation. The residue was dissolved in 0.5 mL of solution B and passed through the cartridge followed by 2.5 mL of solution B. Extraction of VLCFA took Ͻ4 h. After concentration, the extract was dissolved in 100 L (minimal quantity for the autosampler) of n-hexane containing 0.05 g/L butyl hydroxytoluene and analyzed on a Hewlett-Packard 5890A gas chromatograph equipped with a splitless capillary injection system, a flame ionization detector, a fused silica capillary column (25 m ϫ 0.32 mm, Model HP-1) and an autosampler (Model HP7673). The injection volume was 2 L, and the temperatures at the injection and detection ports were 250°C and 285°C, respectively. The column temperature was increased from 60°C to 180°C at 15°C/min, to 250°C at 4°C/min, to 280°C at 15°C/min, and maintained at 280°C for 5 min. Helium was the carrier gas. Peaks were identified by comparison of retention times with those of authentic standards and measured by area.
The ratios of lignoceric acid (C 24:0 ) to behenic acid (C 22:0 ) in dried blood spots on filter paper are shown in Fig. 1 , top. The mean Ϯ SD values were 1.6 Ϯ 0.2 in the 21 controls between ages 1 week and 1 month, 1.3 Ϯ 0.1 in the 19 control infants of age 1 year, 1.2 Ϯ 0.1 in the 27 controls between ages 2 and 5 years, and 1.3 Ϯ 0.1 in the 25 controls between ages 6 and 15 years. The ratio was Ͼ1.5 in all ALD patients (1.8 Ϯ 0.2) (10 with childhood ALD and 2 with adrenomyeloneuropathy) and in 6 of 7 carrier mothers (1.6 Ϯ 0.2) (Fig. 1, bottom) . The C 24:0 /C 22:0 ratios did not change at room temperature within 10 days. There were no significant sex-or age-related differences in the ratios of C 24:0 /C 22:0 in serum sphingomyelin [8] . In our previous data, the ratio of C 24:0 /C 22:0 in the control group was 0.6 Ϯ 0.1, whereas that of ALD patients was 1.4 Ϯ 0.2 [8] . About one-half of the control newborns showed C 24:0 /C 22:0 ratios higher than the cutoff point. There may be an age-dependent difference in fatty acid composition of erythrocytes. It would be difficult to screen ALD patients in the neonatal period with the use of Guthrie paper. All children between ages 2 and 5 years showed ratios Ͻ1.5. ALD patients and many of the carriers could be distinguished. Although our method is not good for the screening of children under age 2 years, patients are in the presymptomatic stage during that period. The ratio of hexacosanoic acid (C 26:0 ) to C 22:0 was not useful for diagnosis because C 26:0 produced a very small peak, and the SD was very wide. Therefore, it is appropriate to screen children between ages 2 and 5 years with a cutoff value of 1.5. Blood sampling is feasible because the health check for infants is performed at ages 4, 10, 18, and 36 months in Japan.
Compared with the previous VLCFA analysis of serum, our method with dried blood spots on filter paper has Clinical Chemistry 43, No. 11, 1997 some merits. First, it requires only 100 L of blood, and the separation of serum is not necessary. Second, it is easy to use, and specimens can be sent by mail. Third, the extraction of fatty acids with the use of disposable prepacked silica Sep-Pak columns [18] is easy and takes a short time, so we can analyze samples from a large number of subjects. The gas chromatograph took ϳ35 min to analyze one sample and 10 min to be ready for the next. At that rate, 32 subjects/day, i.e., 11 680 subjects/year can be analyzed theoretically with one gas chromatograph. Taking into account routine checks and maintenance, ϳ100 gas chromatographs would be enough to analyze all male infants in Japan, 600 000 every year, and the time to measure a sample would be shortened. Although the extraction of fatty acids by our method is more complicated than that of Nishio et al. [17] , the analysis by gas chromatography is easier to deal with and more economical than the gas chromatography-mass spectrometry they used. Therefore, despite some shortcomings such as the age dependence and the false-positive rate at a younger age, our method is useful for the screening of ALD in children. With our method, treatment in the early and presymptomatic stages is possible. Fig. 1 . The ratios of lignoceric acid (C 24:0 ) to behenic acid (C 22:0 ) in the dried blood spots on filter paper (top) and chromatograph of a sample from a control (bottom left) and from a patient with adrenoleukodystrophy (bottom right).
Top: ALD, patients with adrenoleukodystrophy; Carrier, heterozygous mothers; 1W-1M, controls between ages 1 week and 1 month; 1Y, controls age 1 year; 2Y-5Y, controls between ages 2 and 5 years; 6Y-15Y, controls between ages 6 and 15 years. Mean Ϯ SD in each group is expressed by a bar. Bottom, the peaks of C 22:0 and C 24:0 were identified by the retention time. Circadian and ultradian variation is a prominent feature of most endogenous biodynamic processes and has been extensively studied in neuroendocrine systems [1 ] . Interleukin-6 (IL-6) is a multifunctional cytokine that plays an important role in many age-related diseases, including postmenopausal osteoporosis [2, 3 ] . Estrogen has been shown to directly inhibit IL-6 production [4, 5 ] . Very little information on the circadian rhythms and no information on ultradian rhythms of IL-6 or other pro-inflammatory cytokines exists. Recent research has demonstrated a strong reciprocal interaction between IL-6 and the hypothalamic-pituitary-adrenal (HPA) axis [6, 7 ] . Specifically, recombinant IL-6 has been shown to stimulate the HPA axis in humans [8 ] . The recent availability of highly sensitive assays for measuring IL-6 provides the opportunity to study the rhythmic pattern of this cytokine. A study in men, in which samples were collected every 3 h by direct venipuncture, showed a large circadian variation in circulating IL-6 with a peak at 0100 and a nadir at 1000 [9 ] . More frequent sampling is required to elucidate ultradian fluctuations, which typically have periods of 60 to 90 min [10 ] .
For practical reasons, indwelling venous catheters rather than direct venipunctures have been used for studying frequently sampled time series. We designed a study, using an indwelling venous catheter for continuous integrated 15-min sample collection, to establish the normal variations of circulating IL-6 over 24 h in healthy postmenopausal women, and to assess the effect of estrogen replacement therapy on these patterns. In studying the first subject, it became apparent that serum IL-6 reached higher values than expected. Here, we demonstrate that an indwelling peripheral venous catheter leads to local tissue production of IL-6. We also demonstrate that this local production of IL-6 does not affect endogenous cortisol concentrations.
The study protocol was approved by the University of Wisconsin Human Subjects Committee, and the subject gave written informed consent. The study was conducted at the General Clinical Research Center at the University of Wisconsin, Madison.
The subject in this study was a healthy 59-year-old woman who was 6 years postmenopause. A thromboresistant blood withdrawal and tubing set (DakMed, Buffalo, NY) was inserted in a peripheral vein at 0800. Integrated blood samples were collected at 15-min intervals over 25 h by continuous withdrawal with a peristaltic pump (DakMed). Clotted blood samples were centrifuged at 1520g for 10 min, then separated and frozen at Ϫ70°C until IL-6 concentrations were measured in duplicate by a highly sensitive ELISA (Quantakine HS; R & D systems, Minneapolis, MN). This assay kit is validated for measuring IL-6 concentrations in the range 0.094 -10 ng/L. In our laboratory the calibration curve loses linearity at 40 ng/L. The intraassay and interassay CVs for this assay are 3.8% and 7.1%, respectively. The study was repeated after 7 weeks of oral estrogen replacement therapy with 0.625 mg of conjugated estrogen (Premarin) daily. Serum cortisol concentrations were measured in duplicate by RIA (Coat-A-Count, Diagnostic Products Corp.) with an intraassay CV of 10.5%. The reported limit of detection of the assay was 2 g/L (5.5 nmol/L).
Inspection of the first 25-h time series (Fig. 1a) revealed considerable variation in IL-6 concentrations. IL-6 concentrations remained constant at 2.8 -4.7 ng/L for 3 h after catheter insertion, but this was followed by a steep increase to 35 ng/L, almost 10 times the baseline value, after 20 h of sample collection. The IL-6 concentration at 0900 on the second day was much higher than at 0900 on the first day.
In a repeat study, after 7 weeks of estrogen replacement therapy, a sample was drawn from the contralateral arm by direct venipuncture 11 h after the first sample (Fig. 1b) . The IL-6 in this sample measured 2.6 ng/L, while a simultaneously drawn sample from the indwelling catheter measured 24.2 ng/L. After 12 h of sampling, a new venous catheter was placed in contralateral arm. The concentrations of IL-6 from this new site were initially low but again showed an abrupt increase at 3 h. After 22 h, a new catheter was again placed in an arm vein proximal to the site of the first catheter. This time, the IL-6 concentrations remained high (8 -27 ng/L).
The cortisol concentrations measured in the same serum samples as IL-6 demonstrated a normal diurnal variation, with the peak values at 0530 after a nadir at 0200. No increase in cortisol was seen at the time of the rapid increase in IL-6. After 24 h the cortisol concentrations had returned to baseline value (Fig. 1c) .
The use of indwelling venous catheters for studying time series of hormones is the accepted experimental model. In most instances, hormones are secreted from glandular tissue and the measurements represent the concentrations in the systemic circulation. This case study indicates that the onset of increasing IL-6 concentrations 3 h after catheter insertion most probably represents local production of IL-6 and not the circulating concentrations-which indicates that this sampling method may have limitations when time series of immune mediators (e.g., IL-6) are being assessed. The local production of IL-6 is supported by several lines of evidence. First, the values for IL-6 were markedly lower when drawn by direct venipuncture or through a newly placed catheter from the opposite arm. Secondly, the blood concentrations of IL-6 were higher than values reported in other studies of postmenopausal women that used the same assay system [11, 12 ] . Finally, the morning concentrations of IL-6 in Clinical Chemistry 43, No. 11, 1997 samples drawn upon initial catheter insertion were much lower than those at the same time of day but drawn after the catheter had been in the vein for 24 h.
The increased concentrations of IL-6 found when the third catheter was placed in a vein proximal to the previous site of insertion supports the contention that the high IL-6 values derive from local tissue production rather than from the catheter system itself. Importantly, this local tissue production of IL-6 did not appear to increase the systemic concentrations of the cytokine for at least 12 h and did not seem to stimulate the HPA axis, as evidenced by measured cortisol concentrations.
One can speculate that interruption of the vascular endothelial layer by a venipuncture mediates a cytokine cascade sequence that results in increased IL-6 concentrations. Endothelin, which is produced by endothelial cells, has recently been shown to be a potent stimulator of IL-6 production [13 ] . Other cells at the site of injury, such as vascular smooth muscle cells [14 ] , have also been shown to secrete IL-6. One previous study suggested that the increased concentrations of IL-6 in bolus samples collected via indwelling venous catheters every 3 h for 9 h reflect local production of IL-6 rather than circulating concentrations [15 ] . The continuous sampling, more-frequent measurements, and use of a sensitive IL-6 assay in our study confirm this finding and provide a picture of the timing of this local effect, which in this subject occurred at ϳ3 h.
Because of the local tissue production of IL-6, our study did not allow an assessment of the diurnal variation of IL-6. Although there appears to be a faster increase in IL-6 concentrations during estrogen replacement in this one subject, its exact magnitude is likely to vary, both from time to time and from one vein to another. The main reason for this is variation in the rate of blood flow, which ultimately will dilute the locally secreted IL-6 to various extents.
Our results suggest that circulating concentrations of IL-6 may be more reliably assessed by repeated direct venipunctures at a progressively more-distal venous site each time. However, discomfort and inconvenience associated with this method would obviate frequent sampling in human subjects. Researchers and clinicians measuring IL-6 for diagnostic or monitoring purposes should take into account the sample collection method used, particularly if high concentrations are encountered. This local production of IL-6 occurred as early as 3 h after insertion of a catheter at a fresh site and almost immediately from a catheter inserted downstream (proximal) to a previous catheter insertion site. Whether production of other cytokines is similarly triggered after insertion of a catheter is a matter for future investigation. Several previous reports of increased IL-6 in clinical settings may need reevaluation in view of our findings [16, 17 ] . Common methods for the assay of proteins in biological fluids include Lowry [1] , Coomassie Brilliant Blue G-250 protein dye-binding assay (Bradford) [2] , and the 2,2Ј-bicinchoninic acid (BCA) assay [3] . Among them, the Lowry method has been used widely for protein quantification in biological samples. However, many substances commonly used during protein purification interfere with the Lowry assay. To overcome this, the BCA method was developed. This assay is similar to the Lowry method in that both rely on the biuret reaction for generation of a colored complex between peptide bonds and cuprous ions when protein is placed in an alkaline environment containing Cu 2ϩ . Unlike the Lowry method, the BCA method has been found to have exceptional tolerance to nonionic detergents and simple buffer salts. However, sucrose and detergents, biogenic amines, chlorpromazine, penicillins, vitamin C, paracetamol, hydrogen peroxides, or any compound that can reduce Cu 2ϩ to Cu ϩ will produce the characteristic purple color associated with the binding of Cu ϩ with BCA and interfere with this method [4, 5] . It is not surprising that anthracyclines, which are easily oxidized in alkaline media in the presence of metal ions, would produce the necessary reduction of Cu 2ϩ for the formation of a Cu ϩ -BCA complex. In the Bradford method, the Coomassie blue dye binds to primarily basic and aromatic amino acid residues, especially arginine, and forms colored complexes. In this method, interferences may be caused by drug-protein and (or) drug-dye interactions. Because the mechanism of color formation is different in the BCA and the Bradford methods, both methods were considered for interference studies.
The primary objective of this report was to determine whether an anthracycline, e.g., doxorubicin (Dox), may interfere with the measurement of protein concentrations with the BCA and the Bradford assays. We examined the sensitivity and specificity of the BCA and Coomassie Brilliant Blue for Dox in this study. Such findings may have significant implications in the assay of protein when an anthracycline is present.
Dox showed a significant interference in the BCA assay, whether assayed in the presence or absence of a bovine serum albumin (BSA) protein calibrator (Fig. 1) . The interference was found to be linear over the standard protein range, with an immediate appearance of typical assay color without turbidity (even after further dilutions). The reaction of Dox with the BCA reagent at room temperature (RT) for 2 h suggested that a wide range of anthracyclines will react with the BCA reagent to produce the characteristic purple color if the reduction of Cu 2ϩ to Cu ϩ by anthracyclines is dependent on the anthracycline nucleus rather than on the side-chain substitution. The Clinical Chemistry 43, No. 11, 1997 detection limits were 2 ϫ 10 Ϫ4 g/L for Dox and 6 ϫ 10 Ϫ3 g/L for BSA. Although protein shows a nonlinear color response with BCA with increasing concentration, at low concentration the response is linear (Fig. 1) . Dox did not interfere with the Bradford method to quantify protein (not shown).
The development of color associated with the reaction of protein with the BCA reagent is slow at RT and enhanced by increasing the temperature and incubation time [3] . The color developed after 2 h at RT is similar to that developed over 30 min at 37°C. Dox concentrations of 0.01 to 0.10 g/L with different protein concentrations have produced color intensities that are significantly higher than those due to the protein alone (data not shown). These results indicate that anthracyclines will significantly enhance color development produced by proteins at anthracycline concentrations that exceed 2 ϫ 10 Ϫ4 g/L per gram of protein.
Measurement of the total protein concentration of the plasma used to monitor the nutritional status of patients receiving chemotherapy [6] , and changes in serum and urine protein may reflect chemotherapy-associated nephrotoxicity [7] . When calculated for a healthy individual, the plasma concentration of Dox or its metabolites is expected to be Ͼ35 mg/L, as Ͼ75% of Dox is bound to plasma proteins [8, 9] . Therefore, plasma concentrations of anthracyclines, including both the parent and the metabolites, are expected to be Ͼ0.2 g/mg of protein. At this low drug-to-protein ratio Dox would not increase the protein concentration significantly when measured by the BCA method.
Anthracycline derivatives have been widely used in experimental therapeutics. For example, anthracyclines such as daunomycin have been loaded into lipoproteins and their distribution in plasma proteins has been studied [10] . To quantify the drug associated with lipoprotein, it is essential to determine the protein concentrations of the lipoproteins. In all drug loading experiments, the anthracycline concentration was found to be Ͼ0.10 g/L [11] and as high as 0.29 g/L [12] . In these cases, the ratio of Dox to protein was high enough (for example, 25 g drug/mg of protein) to interfere in the color development of protein in the BCA method by Ͼ50%. The protein concentration measured by the BCA method would be 1 g/L with 25 g of Dox/mg of protein when the actual protein concentration was Ͻ0.5 g/L. The magnitude of interference is higher when the drug-to-protein ratio is higher (Fig. 1) . Protein concentration is used as a bench mark to quantify cells and to express activity of an enzyme. In many cytotoxicity and enzymatic studies, the Dox concentration was found to be significantly high (7 g to 0.29 mg of Dox/mg of protein) [12] . The results from our studies indicate a significant increase in the color development of the BCA reagent with Dox in a concentration-dependent manner in the BCA method but not in the Bradford assay.
This study was supported in part by a research grant to H.L. by the Banting Research Foundation. Myoglobin is a 17-kDa single-chain hemoprotein found in skeletal and cardiac muscle. This heme protein facilitates the movement of oxygen into cells and provides for local storage of oxygen. Myoglobin is found in the circulation as a result of muscle damage. Several conditions are associated with the release of myoglobin into the circulation, including myocardial infarction, trauma, ischemia, surgery, exercise, rhabdomyolysis, and other myopathyassociated disease states [1] [2] [3] .
Stability of a Control Material Suitable for Quantitative
The quantitative measurement of myoglobin in urine is clinically important in diagnosing myoglobinuria, which can subsequently induce acute renal failure, particularly in posttrauma, surgery, and rhabdomyolysis patients. Recent studies have suggested that patients with a urine myoglobin concentration Ͼ20 000 g/L, particularly with a decreased myoglobin clearance rate (Ͻ4 mL/min), are at increased risk for decreased renal function [4, 5] . Although the mechanism for myoglobin-induced acute renal failure has not yet been elucidated, large amounts of myoglobin present in the tubules may precipitate, particularly under acidic conditions, resulting in increased intratubular pressure and, subsequently, the decreased glomerular filtration rate [6] and (or) free-radical generation from inorganic iron may cause renal damage [7] . The identification of the early clinical sequelae of myoglobin-2202 Technical Briefs uria is important for enabling administration of prophylactic treatment for acute renal failure [8] .
Quantitative methodologies, including automated immunoassays, have been advocated and are becoming more widespread for the measurement of urine myoglobin [4, 5, 9] because previous qualitative methods have been shown to be unreliable [9, 10] . As with all quantitative assays, it is imperative that appropriate control specimens be analyzed in parallel with all patient specimens. Ideally, such materials should be matrix-matched and treated in a manner identical to that of all patient specimens. The concentration of the material should be at or near those relevant to clinical decision concentrations. In addition, this material should be stable over an extended period of time. To date, a suitable commercial quality-control (QC) material that meets these criteria is not available. The purpose of this study was to evaluate the suitability and long-term stability of an in-house prepared urine pool for use with quantitative urine myoglobin assays.
A pool was prepared from urine obtained from several patients with increased urine myoglobin concentrations. The pool was diluted with buffer [100 mmol/L phosphate buffer, pH 9.0, containing 70 g/L bovine serum albumin (BSA) and 0.1 g/L sodium azide] to a final myoglobin concentration of ϳ20 000 g/L. To avoid repetitive freezing/thawing, 100-L aliquots of the urine myoglobin pool were stored in polyethylene vials at Ϫ80°C. The target concentration of the pool was determined to be 18 800 g/L as determined by analysis of five aliquots in duplicate over 5 days. A tentative range (mean ϩ 2SD) of 16 200 -20 900 g/L was established with this data and was subsequently used as a target value in assessment of the stability of the pool over the following 6 months. The mean and SD of all QC data were evaluated monthly and at completion of the study and compared with this initial range.
Urine myoglobin concentration was determined by modification of the serum Stratus II immunoassay (Baxter Healthcare Corp.) as previously described [4] . As part of our routine workload, the in-house QC material was analyzed in parallel with at least one concentration of a commercial creatine kinase (CK)-MB/myoglobin immunoassay control (Dade International). Both patient urine and urine QC were treated in an identical manner by diluting 1:101 as follows: Twenty microliters of either urine myoglobin QC or patient sample was pipetted into 2 mL of buffer (described above) and vortex-mixed for 30 s before the analysis. This dilution was previously determined to be most effective in detection of clinically relevant urine myoglobin concentrations. Each vial of QC was used once and the remainder discarded. The Dade serum control material was analyzed without dilution.
The values obtained with the in-house urine myoglobin control (n ϭ 199) as well as 194 runs of the commercial serum material over a period of 179 days are shown in Table 1 . The overall mean ϩ SD of the urine myoglobin QC was 19 200 ϩ 2020 g/L (CV ϭ 10.5%). There was no difference between the mean of the initial target determinations and the monthly means obtained over this time period (data not shown). Similarly, no difference was observed with the serum control material over this period.
Over the 6-month study period a total of 16 outliers were obtained with the in-house QC material and 15 with the Dade material. In 13 of these 16 cases, the results were within allowable limits upon repeat analysis. In many cases, the initial cause for rejection may have been a dilution error by one of 38 technologists who were responsible for specimen analyses. Further corrective action was required in the remaining three cases. In two cases, the outlier was caused by a reagent problem. The final one required recalibration.
The CV of the in-house material was double that of the commercial serum material (10.5% vs 5%). This increased CV may result from the 101-fold dilution before analysis. The fact that the QC was diluted in a manner identical to patient specimens is beneficial in detection of possible dilution errors before analysis by the technologist.
The use of this material offers several advantages for this application. The target concentration of the material is clinically relevant (ϳ20 000 g/L). Perhaps the greatest advantage lies in the fact that the material is treated identically to patient specimens (as discussed above). This matrix-matched material is useful for detection of errors in dilution and for detection of problems that may occur with the diluent. Secondly, the stability of the material prepared in this manner (at least 6 months) allows for preparation of a large lot, thus obviating the need for weekly preparation of commercially available serum ma- Celiac disease (CD) is an autoimmune disorder associated with a small bowel lesion induced by toxic gliadin components [1, 2] . In this condition, an antigen peptide from ␣-gliadin, corresponding to the amino acid sequence between residues 31 and 49, initiates the cellular immune response, which is mediated by gliadin-specific T lymphocytes [3] . Antigen recognition by T lymphocytes in CD mainly occurs if the gliadin-derived peptides are carried by the HLA class II molecules HLA-DQ2 or HLA-DR4 [4, 5] . Thus, the genetic susceptibility towards CD derives from inheriting certain HLA class II alleles encoding for the above-mentioned specific molecules. Among the CD-HLA associations that have been described so far, the one caused by the presence of alleles DQA1*0501/DQB1*0201 (encoding for the DQ2 molecule) is present in most cases, whereas the DRB1*04 alleles (encoding for the DR4 molecule) occurs almost invariably in the other cases [5, 6] . In fact, these two associations characterized Ͼ95% of the affected celiac patients in European populations [7] .
The aim of our study was to improve a PCR-based methodology for the rapid typing of the DQA1*0501, DQB1*0201, and DRB1*04 alleles, and thus provide an additive simple tool for the diagnosis of CD.
DNA was extracted from 5 mL of fresh whole blood in EDTA by proteinase K treatment followed by phenolchloroform extraction [8] . Isolated DNA samples were quantified by UV spectrophotometry at 260 nm absorbance and diluted with distilled water to the concentration required for PCR (100 ng/L). We examined the DNA of three subjects whose HLA serological specificities, previously studied, were: (a) DQ2/DQ5, (b) DQ5/ DQ7, and (c) DR4/DR16. The first haplotype showed the DQ2 molecule that is strongly associated with DQA1*0501, DQB1*0201 genotype and so represented a positive DNA control for these alleles. The second haplotype lacked the DQ2 and DR4 molecules and so we used it as a negative control for the other alleles. The third haplotype showed the DR4 molecule encoded by DRB1*04 alleles, thus representing a positive DNA control for these alleles.
Two reaction mixtures were used, one for the amplification of the DQA1*0501 and DQB1*0201 alleles, and the other for the identification of the DRB1*04 alleles, with the allele-specific primers described in Table 1 . The sequences of these primers differed in 2 or 3 nucleotides from those of the other known alleles at the same HLA loci. To increase primer specificity, we introduced a mismatch at their 3Ј end [9] . We used exon 10 of the pyruvate kinase gene [10] in the first mix and exon 10 of the cystic fibrosis gene [11] in the second mix (see Table 1 ). These two primers did not match the HLA allelic sequences and so their PCR products (respectively 238 bp and 491 bp length) represented internal positive amplification con- PCR products were separated by agarose gel electrophoresis. Thirty microlitres of the PCR reaction mixtures were added to 5 L of loading buffer (300 mL/L glycerol stained with bromphenol blue and xylene cyanol) and loaded in a 3% agarose gel prestained with ethidium bromide (0.5 g/mL gel) (Sigma Chemical Co.). Electrophoresis was performed at 100 V for 40 min in 1ϫ TBE buffer (89 mmol/L Tris base, 89 mmol/L boric acid, 0.2 mmol/L EDTA). PCR products on gel were visualized by UV illumination as bands of 144 bp (DQA1*0501), 110 bp (DQB1*0201), and 177 bp (DRB1*04) and then photographed. Fig. 1 shows an example of HLA typing obtained with our procedure on DNA samples from the three previously HLA-characterized (serologically) individuals. All three HLA-DQA1*0501, DQB1*0201, and DRB1*04 alleles appeared as well-separated bands.
In the diagnostic iter of gastrointestinal malfunction, the finding of the HLA DQA1*0501, DQB1*0201, and DRB1*04 alleles increases the possibility of having CD [7] . Various methods have been described for DNA typing at the HLA level, mainly for histocompatibility testing. These procedures involve a combination of PCR amplification with restriction fragment length polymorphism [12] , sequencing, oligonucleotide probing, or sequencespecific primers [13] [14] [15] [16] , all of which are time consuming and expensive when used for CD diagnosis. We have devised a rapid, accurate, and cost-effective PCR-based method to type, with a high level of resolution, the HLA-DQA1*0501, DQB1*0201, and DRB1*04 alleles. The advantage of our method is that it does not require radioactive material and that, after the same PCR program, the three most frequently CD-associated alleles are visualized on the same gel, within ϳ2 h from DNA sample collection. We have used this method to examine Ͼ100 celiac patients and ϳ30 patients affected by other gastrointestinal syndromes clinically similar to CD. The results are similar to those obtained in other populations, with other methods (manuscript in preparation). We suggest that this procedure could represent an adjunctive tool in the diagnostic approach to CD; it is suitable for family screening, epidemiological studies, and for diagnosis particularly when histological and immunological patterns are ambiguous. AC-1 and AC-2, amplification controls: exon 10 of pyruvate kinase gene and exon 10 of cystic fibrosis gene, respectively. Primers used as internal positive amplification controls AC-1 and AC-2 are also reported. The first oligo is located upstream and the second one downstream along the genes. Renal transplantation has come to be accepted as standard treatment for patients with terminal kidney failure. Because the physiological state of the renal transplant recipient is unstable, he or she is monitored with a welldefined protocol that is strictly followed by clinicians. Renal dysfunction is a common complication due to various problems, especially drug toxicity, and rejection is an ever-present danger [1] . To detect episodes of rejection, clinicians use empirical criteria derived from experience that is mainly based on changes in creatinine concentrations. Posttransplantation monitoring, which includes frequent analysis of a number of constituents, generates large amounts of data. With this information, finding objective, early indicators that predict trends toward complications before the patient's condition is seriously compromised would be beneficial, so that preventive actions could be taken.
Data from biological variation (BV), the normal fluctuation around the homeostatic set point, has been used to evaluate the significance of changes in serial results [2] . Therefore, it can provide clinicians with an indication of future patient status: A change between two consecutive observations higher than the established variation around the homeostatic set point could signal the beginning of a complication. However, the components of BV, sensitive and specific enough to characterize a "certain state of health" from the start of crisis, can be investigated only when a stable situation that denotes equilibrium has been demonstrated in the specific pathology.
The aims of this work were to delineate the stable period after renal transplantation for six serum analytes expected to reflect instability/rejection, and to calculate within-and between-subject BV, indices of individuality (II), and critical differences (CDs) between serial results and compare outcome with published data in healthy subjects to determine whether BV data can predict crises in this population.
We studied 19 patients (12 men and 7 women), 19 to 64 years old, with chronic renal insufficiency who had received an orthotopic kidney graft. Permission for enrollment in the study was obtained from all patients, as required by the Helsinki II protocol.
Serum specimens were collected according to the usual hospital follow-up protocol designed by the nephrologists for these patients, as summarized: (a) First week posttransplantation, daily; (b) from the second to fourth week, twice a week; (c) from the first to the third month, weekly; (d) from the third to the sixth month, every 15 days; (e) from the sixth to the twelfth month, once a month; (f) from the first year on, every 2 or 3 months, indefinitely.
Stability in posttransplantation patients is routinely verified through a combination of clinical, analytical, and imaging parameters: clinical normality as indicated by symptomatology, physiological constants, diuresis, weight, physical examination, etc.; analytical profile with particular attention directed to the stability of creatinine results (expected to differ Ͻ25% between two consecutive samplings); and doppler echography. The data from our 19 patients was studied for 2 years posttransplantation, and during this time there was no evidence of crisis or rejection according to the nephrologists' protocol.
The conditions of specimen collection were standardized to minimize the effect of collection. Specimens were collected into evacuated blood-collection tubes without anticoagulant. The specimens were allowed to clot at room temperature and were centrifuged at 3000g for 15 min. We separated the serum, and quantities were analyzed. The study was conducted in real time throughout.
Six serum biochemistry analytes were determined: creatinine, urea, urate, sodium, potassium, and chloride.
Establishment of the homeostatic point: The homeostatic point for each analyte was derived from the period of maximum stability.
1) Determination of the beginning of the stable period: The analytic results from each analyte in each patient were represented graphically from the beginning of the posttransplantation period. Visual inspection of the graphs showed high results in the first determinations 2206 Technical Briefs that decreased to a point after which results remained constant over time (from negative slope to horizontal lines) in some of the analytes. This point was considered to be the beginning of the stable period and was called "point zero." Point zero and the stable pattern were seen very clearly in the creatinine analyses and were confirmed in the urea graph; however, in the remaining analytes a clear inflection point was not observed. Therefore in each patient, point zero for all the quantities studied was derived from the creatinine results.
2) Determination of the end of the stable period: Results were normalized according to the start value [3] : the ratio of each result from a patient with respect to his value at point zero was calculated.
The CV of the ratios of the 19 patients (normalized CV) was calculated and the difference between the CV for each sampling day and the CV for point one (the CV at point zero is 0) were depicted on a graph, against the analytical variation of the method for each constituent. When the difference between the normalized CV was found to be higher than the analytical CV, stability was considered to have ended.
BV calculations: Analytical imprecision (s 2 a ) was calculated through control materials, averaging the routine data for 12 months, and using the control concentration closest to the mean of the concentration values found in the 19 patients studied.
Before performing calculations with the patients' results, the Cochran test [4] was applied to exclude outlying values from the individual subjects, and the Reed test [5] to eliminate mean outlying values.
The ANOVA test [6] was used to estimate withinsubject (s CDs between consecutive results were calculated after confirming with the Kolmogorov-Smirnov test [6] that the (s 2 iϩa ) data were normally distributed; subsequently, the one-tail formula (␣ ϭ 0.05) was used to detect only significant increases:
To derive BV data, the stable period within the pathology has to first be defined: The more precisely the stable period is delineated, the more robust will be the indicators produced. The beginning of posttransplantation stability was determined by examining the slopes of the quantities studied. We considered that a clear inflection (and subsequent maintenance) of the slope in more than one quantity simultaneously would signal the beginning of stability. For all 19 patients, creatinine and urea showed this pattern and were considered valid for our purposes.
The beginning of the stable period was found between the first and second month posttransplantation, although the exact moment when it occurred was not necessarily the same in all patients. The fact that at this time the nephrologists' protocol reduces the required analyses to a frequency of one per week indicates that the empirically based criteria also perceive stability at this time.
To minimize interindividual variation and to facilitate the detection of relative changes among patients, all results were normalized [3, 7, 8] . Fig. 1 shows the difference between the normalized CV at each sampling day and the CV at point one, in relation to the analytical CV (parallel line to the x-axis) for creatinine. The period of stability was considered to conclude when the CV of the difference was higher than the analytical CV. This occurred within an interval of eight determinations (that starts between 1 and 2 months after surgery), when follow-up protocol analyses are performed once a week, and is maintained for an average of 3 months, depending on the patient. Table 1 shows the components of analytical and biological variation found in this study, expressed in terms of CVs. Data from healthy subjects obtained by averaging results from previous works [9, 10] are also exhibited.
When studying the components of BV, the analytical component (CV a ) is lower than half the within-subject component (CV i ) for all constituents studied (except chloride and sodium), demonstrating that the use of "real time" analytical data is appropiate for studying BV. Browning et al. [11] recommended that when studying BV, the analytical component should be Ͻ20% of the total variance found. The analytical difficulties for chloride and Clinical Chemistry 43, No. 11, 1997 sodium are similar to those found by other authors in similar studies [12, 13] .
BV data from healthy subjects have been compiled in two well-known articles [9, 10] . Few works have dealt with BV in pathological status. Fraser and colleagues reported that the within-subject and between-subject variation for certain analytes in patients with renal dysfunction and cardiac infarction are the same as in healthy subjects [13, 14] . Hö lzel [15, 16] , however, shows discrepancies in specific pathological situations. Our data show that within-subject variation was higher in the kidney graft recipients than in the healthy population, being most evident in the creatinine, potassium, urate, and urea results. We found no differences in the between-subject variation, except for potassium.
We studied BV to determine if analytical results from the routine monitoring protocol could be used as predictors of functional alteration in renal transplant recipients. To know which constituents are suitable as early indicators of negative evolution in pathological situations, the II are determined. Creatinine, urate, and urea, with II of ϳ0.6, are suitable for monitoring [2] .
Harris and colleagues proposed a formula derived from within-subject variation to interpret CDs in serial results [17, 18] . We found that CDs were ϳ28% in creatinine, urate, and urea. This figure is very close to the 25% criteria used by the nephrologist in their protocol. Moreover, none of the 19 patients surpassed this difference over the study period, indicating that no significant changes occurred.
The other constituents provided no information for the purpose of predicting functional alteration. Thus, an interpretation of serial results from the combination of creatinine, urate, and urea analyses could be a method for early detection of possible crises in posttransplantation patients.
In conclusion, this work describes a model for studying BV in a nonhealthy state by using available laboratory data. It shows a method for demonstrating stability within the pathology and for deriving the components of BV. [2, 3] . Methods of analysis in biological fluids include gas chromatography (GC), GC-mass spectrometry (MS), HPLC, and immunoassays [4] . Chromatographic methods usually appear to be complex and unable to provide chemical identification under screening conditions. We present in this study a simple and rapid GC procedure with a nitrogen-phosphorus detector (NPD) for the simultaneous determination of seven frequently requested new ADPs in plasma. As far as we know, no previous report has been published on the concurrent determination of ADPs by using a common extraction procedure and GC analysis. This assay was developed for the analysis of amoxapine, dothiepin, fluoxetine, fluvoxamine, medifoxamine, mianserin, and viloxazine. The reagents, apparatus (Varian-Star 3400 CX coupled to a Fisons-Chromcard for Windows Software), and procedure for the separation and measurement of the analytes have been previously described, according to the method for fluoxetine [5] . Briefly, the patient's alkalinized specimen (1 mL of a 20% ammonia solution mixed with an equal volume of serum), with added protriptyline as internal standard (IS) (15 L of a 10 mg/L working solution in ethanol), is extracted in a one-step procedure with hexane:dichloromethane:isoamyl alcohol (57:42:1 by vol). The residue is dissolved in 50 L of ethanol and directly chromatographed on a 25 m ϫ 0.32 mm (i.d.) OV1 capillary column (25-m-thick film) with helium as the carrier gas. The method gives a linear response to at least 2000 g/L. The limits of detection ranged between 0.2 and 2.0 g/L and the limit of quantification was established as between 0.5 and 5.0 g/L (n ϭ 5). Intraassay and between-day CVs were Յ10% (n ϭ 10). The mean overall absolute recoveries (n ϭ 5) ranged from 65% (medifoxamine) to 97% (fluoxetine). Plasma from drug-free patients did not exhibit significant peaks in the 30-min retention range. Calibrators and controls were prepared with drug-free plasma of healthy volunteers.
We studied 57 compounds that can potentially interfere in plasma. A complete list, with retention times (t R s), is given in Table 1 . ADP metabolites may also be detected in plasma patients. So whenever possible, we tested the metabolites of the various analytes. No interference came from endogenous plasma constituents eluting during the complete analysis set. The potential for interference was judged by the presence of an interfering peak for coextracted drugs, the retention time of the peak, and peak height in relation to the drug's plasma concentration. Many psychoactive drugs were tested on the OV1 capillary column because they could be associated with ADPs. Of all the drugs tested, only trimipramine coadministration could modify the results, since its metabolite, the desmethyltrimipramine, has the same t R as the IS (18.33 min). If a peak appeared at t R 18.16 min, it is highly probable that a tricyclic ADP (trimipramine or imipramine) was administered. No quantification is available in the case of trimipramine coadministration. Therefore only GC-MS appeared to be able to provide unequivocal chemical identification under screening conditions for toxicological samples. Fours drugs also showed peaks that would partially overlap within Ϯ0.1 min t R of analyte peaks: cocaine and amitriptyline with mianserin, codeine with dothiepin, and desipramine with protriptyline. The GC-NPD method was applied to plasma samples from depressed patients, chronically treated with ADPs, who had intentionally ingested high doses of their treatment.
In the case of a patient overdosed with dothiepin, our method allowed a successful resolution of dothiepin (t R 19.28 min) with its two major metabolites, the northiaden (t R 19.37 min) and the dothiepin sulfoxide (t R 19.69 min), in spite of close t R s. The main advantages of this technique are based on: 1) Use of NPD detector: The introduction of new generations of NPD detectors allows signals of high stability during long-term operation, and the nitrogencontaining structure of ADPs is compatible with a high sensitivity for NPD detection. The method's measurement range (0.5-2000 g/L for amoxapine and dothiepin and 5-4000 g/L for fluvoxamine) makes it possible to avoid the potential need for sample dilution in cases of intoxication, and it also has a low detection limit (Յ2 g/L).
2) Simplicity of the procedure: The simple addition of an ammonia solution before the initial introduction of plasma and other reagents for extraction minimizes adsorption of ADPs on glass and also makes the biological material slightly alkaline (pH Ͼ10) for the extraction. Protriptyline was chosen as IS because this compound either has been withdrawn from the market in some countries, or is not as widely used as tricyclic ADPs. The decrease in the proportion of hexane (57%), the addition of a more polar solvent, dichloromethane (42%), and isoamyl alcohol (1%) to break up emulsions was shown to be preferable for recovery of tricyclic ADPs and fluoxetine, as we previously described in recent reports [5, 6] . Overall recoveries ranged between 65% and 97%.
3) Good resolution: The benefit of capillary GC essentially resides in a high resolution, allowing for peak resolution of peaks with t R s within Ͼ0.1 min of each other.
4) Powerful detection tool for ADPs: Automated immunoassays are unable to detect ADPs unrelated to the imipramine structure [4] . Chromatographic procedures are the most viable techniques used to identify and determine these drugs. The benefits of monitoring ADPs have been much discussed, but in many cases, the information obtained has proved useful for the management of psychiatric patients [7] .
In conclusion, the present assay is one of the most sensitive and specific assays for second-generation ADPs. Its ability to measure several new ADPs simultaneously makes it particularly useful for toxicological emergency and for managing psychiatric patients treated with ADPs.
